![]() Los Angeles County officials said they have no plans for new public mask mandates - a sign of how COVID-19 policies have changed in the back-to-normal era.Įven Dr. Eric Topol, director of the Scripps Research Translational Institute, about a new coronavirus variant called BA.2.86, “it turned out to be a real nothingburger,” Moore said.Ĭalifornia Why no one is talking about new mask rules even as COVID-19 rises in L.A. “Editorial FOMO drove summer surge worries,” Moore said, using an acronym for “fear of missing out.” Despite worrying comments and tweets by physicians such as Dr. He is skeptical of the significance of the recent uptick in COVID-19 hospitalizations, and criticized social media posters who have raised fears about new viral strains that don’t seem to pose any fundamental challenge to the new vaccines. is “not a cookie-cutter population.” Its people have by now been exposed to a bewildering combination of vaccines, boosters and different strains of the virus.įearmongering has distorted the threat of the virus, Moore said. Who exactly will benefit most is impossible to predict because the U.S. It was actually compared with a different bivalent formulation that targeted XBB.1.5 and the BA.4/BA.5 subvariants.Ī preliminary study of the new Moderna vaccine showed that it increased antibodies to various coronavirus strains, though it wasn’t clear how much protection it would offer, nor for how long.Ĭhristopher Ridley, a Moderna spokesperson, said the updated vaccine was well matched to current viral strains.īut John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, said the new vaccine is unlikely to be “a game changer.”įor healthier adults and children, “it’s a boost in protection for a few months,” Moore said. 11, 2023 A previous version of this article said the new Moderna vaccine was compared with the formulation released last year. About 170 million flu vaccines were distributed last flu season in the U.S., so a combination product could lock in a large market for COVID-19 vaccines as well.ģ:39 p.m. Within a few years, both companies expect to be producing combination vaccines protecting against influenza, COVID-19 and possibly respiratory syncytial virus, or RSV. ![]() Pfizer expects about $14 billion this year. ![]() Moderna CEO Stéphane Bancel told investors in August that the company expected its global COVID-19 vaccine sales to be $6 billion to $8 billion this year, depending on uptake in the U.S. Pfizer and Moderna continue to make billions of dollars in sales of COVID-19 vaccines, although they are producing fewer doses. “The last thing we need are financial barriers that would enhance disparities,” Schaffner said.Ī 1993 law requires the federal government to pay for childhood vaccines recommended by the ACIP, and more recent legislation requires coverage of adult vaccines within 15 days of an ACIP recommendation. (Pfizer spokesperson Amy Rose said the price was “consistent with the value delivered” and reflected higher expenses to provide the shots commercially.)īut a partial recommendation could leave the very groups who suffered most during the pandemic - minorities and other disadvantaged groups - unable to get vaccinated if they want but can’t afford to. Kathryn Edwards, a professor of pediatrics at Vanderbilt and a member of an ACIP working group on COVID-19. It’s “pretty awful” that Pfizer and Moderna, the two main COVID-19 vaccine producers, have decided to charge up to $130 a shot, compared with $30 last year for the booster, which was produced under government contract, said Dr. Science & Medicine The Path From Pandemic: How COVID-19 will change American lifeĪn occasional series of stories about the transition out of the COVID-19 pandemic and how life in the U.S.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |